Donald Templin: I’m sorry, John, repeat that question. This is on all the alternatives.
John Barnidge: Yes. So, on alternatives, you’re now going to, it sounds like you’re going to pre-release it going forward. Can you talk about your performance in the third quarter specifically? It changed from the second quarter and within that given, it’s a one quarter lag asset, is there a look forward you can provide at all into the fourth? Thank you.
Donald Templin: No. I think really, what we’re planning to do, we had — we give the information around the alt’s performance below our long-term expectations, right? So that’s a 9% general expectation around that. We call that out as a notable item. And what we’d like to do is a few days after the end of the quarter, we will actually, as part of our 8-K process when we publish some other information, we will provide what we achieved in the current quarter, so that you all can build that into sort of your consensus number or your expectations around our performance. So, what’s happening now is you take a view around that. We publish as part of our earnings and there’s a 30-day period there that we may be misaligned on prepayment or the alternative below or above expectations. So, our goal here really is to give you that information early, so that you can work it into your overall estimate.
Operator: Thank you very much. Our next question comes from Wilma Burdis with Raymond James. Please proceed with your question.
Wilma Burdis: Hey, good morning. Could you guys provide a few additional details on the legal reserve recorders?
Rob Grubka: Yes. this is Rob. It sits within the health business. We won’t get into details. It’s not at that stage of things, but we don’t have enough to size it and adjust it in the results this quarter.
Heather Lavallee: And the only thing I’d add, Wilma, is that we do consider it a non-repeatable item.
Wilma Burdis: Okay, thank you. And could you give a little bit more color on the improved outlook for the health benefit ratio and what’s driving that?
Donald Templin: Yes. So, as you look at our business mix, the primary driver of bringing it down 1%, so 69% to 72% versus what was 70% to 73% is really the mix of business. So, as we’ve successfully grown for a number of years now at a really fast rate, our voluntary business, it’s really a reflection of that shift. And obviously, it’s — this is a range we’ll continue to look at overtime as the mix shifts around further. And what we’re trying to do is grow responsibly, do it in a way, and I think you’re seeing that show up that is going to lead to the bottom line.
Heather Lavallee: And if I can just add, we’re incredibly proud of the results that Rob and team have delivered in health this year. If you just think about annualized in-force premium growth, 15% well above our 7% to 10% target, the 36% growth in revenues, and then to still on top of that deliver a loss ratio that’s below our target. And we’ll take that all day long. And as Don mentioned, as we mentioned in our comments, we’re excited about the pipeline that the team has in front of us.
Operator: Thank you. Our next question comes from Tom Gallagher with Evercore ISI. Please proceed with your question.
Tom Gallagher: Good morning. A follow-up for Christine on, I am the 10 billion pipelines related to the U.S., you said. can you talk a little bit about what you’re thinking about Europe ex NNIP? How has it been performing, excluding NNIP? And based on what you’re seeing winding up there, would you also expect that to be an inflow contributor for 2024?
